Home Cart Sign in  
Chemical Structure| 431898-65-6 Chemical Structure| 431898-65-6

Structure of PS-1145
CAS No.: 431898-65-6

Chemical Structure| 431898-65-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PS-1145 is an IkappaB kinase (IKK) inhibitor with IC50 of 88 nM.

Synonyms: IKK Inhibitor X

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PS-1145

CAS No. :431898-65-6
Formula : C17H11ClN4O
M.W : 322.75
SMILES Code : O=C(C1=CC=CN=C1)NC2=CC(Cl)=CC3=C2NC4=C3C=CN=C4
Synonyms :
IKK Inhibitor X
MDL No. :MFCD18089825
InChI Key :JZRMBDHPALEPDM-UHFFFAOYSA-N
Pubchem ID :9949093

Safety of PS-1145

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of PS-1145

pyroptosis
TLR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RHypoE-7 cells 20 µM 1 hour PS1145 significantly reduced the activation of the IKK-β/NF-κB signaling pathway and decreased the inflammatory response. J Neuroinflammation. 2014 Mar 27;11:60
K562-STI-R cells 25 µM 16 hours PS-1145 in combination with dasatinib and U0126 resulted in a 65% decrease in survival of IM-resistant cells. Mol Oncol. 2018 May;12(5):630-647
NCIH460 10 µM 24 hours PS-1145 reversed the inhibitory effect of IL-32γ on the binding of DNMT1 to the TIMP-3 promoter Cell Death Dis. 2018 Feb 21;9(3):306
A549 10 µM 24 hours PS-1145 reversed the inhibitory effect of IL-32γ on the binding of DNMT1 to the TIMP-3 promoter Cell Death Dis. 2018 Feb 21;9(3):306
Human naı ¨ve CD4+ T cells 3 µM 24 hours To evaluate the effect of PS-1145 on the proliferation of CD28-costimulated naı ¨ve CD4+ T cells, results showed that PS-1145 significantly inhibited cell proliferation. Immunology. 2010 Oct;131(2):231-41
C666-1 NPC cells 0.2 mM 48 hours Inhibition of NF-κB signaling, downregulation of Qp-EBNA1 expression Cancers (Basel). 2018 Apr 16;10(4):119
TPC1 10 µM 5 days PS1145 alone had no significant effect on TPC1 cell proliferation, but combined with PD0325901, it significantly inhibited proliferation by 43% Thyroid. 2008 Aug;18(8):853-64
KAT10 10 µM 5 days PS1145 alone caused ~40% inhibition in KAT10 cells, and combination with PD0325901 resulted in a further 25–95% inhibition Thyroid. 2008 Aug;18(8):853-64
KAK1 10 µM 5 days PS1145 alone caused ~40% inhibition in KAK1 cells, and combination with PD0325901 resulted in a further 25–95% inhibition Thyroid. 2008 Aug;18(8):853-64
CML CD34+ cells 10 µM 7 days PS-1145 in combination with dasatinib and U0126 resulted in elimination of 65% of IM-resistant cells and reduction in the colony-forming capacity of CML CD34+ cells in methylcellulose assays by 80%. Additionally, CML CD34+ cells cultured with the combination of inhibitors showed reduced MAP3K8 transcript levels. Mol Oncol. 2018 May;12(5):630-647

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Diet-induced obese mice Central administration (third ventricle) 1 μg Single injection To study the effect of PS1145 on leptin-induced BP elevation, results showed that PS1145 significantly prevented leptin from increasing BP in obese mice J Biol Chem. 2016 Jul 15;291(29):15131-42
Mice GVHD model Intravenous injection after ex vivo treatment 10 µM Single treatment Significantly inhibited GVHD lethality Am J Transplant. 2009 Mar;9(3):452-62

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.10mL

0.62mL

0.31mL

15.49mL

3.10mL

1.55mL

30.98mL

6.20mL

3.10mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories